Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 36322-90-4 | Product Number: P1905
Piroxicam
Purity: >98.0%(T)(HPLC)
Synonyms:
- 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide
- 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-Dioxide
Product Documents:
Size | Unit Price | Belgium | Japan* |
---|---|---|---|
10G |
€ 185,00
|
1 | 9 |
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Product Number | P1905 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__1__5H__1__3N__3O__4S = 331.35 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Store Under Inert Gas | Store under inert gas |
Condition to Avoid | Air Sensitive,Heat Sensitive |
CAS RN | 36322-90-4 |
Reaxys Registry Number | 627692 |
PubChem Substance ID | 125307705 |
Merck Index (14) | 7506 |
MDL Number | MFCD00057317 |
Specifications
Appearance | White to Light yellow powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Melting point | 199.0 to 203.0 °C |
NMR | confirm to structure |
Properties (reference)
Melting Point | 201 °C |
Maximum Absorption Wavelength | 358(H2O) nm |
GHS
Pictogram | |
Signal Word | Danger |
Hazard Statements | H301 : Toxic if swallowed. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
EC Number | 252-974-3 |
RTECS# | DL0705000 |
Transport Information:
UN Number | UN2811 |
Class | 6.1 |
Packing Group | III |
HS Number | 2934999090 |
Application
Piroxicam: A Nonsteroidal Anti-Inflammatory Drug (NSAID) with Antitumor Activity
Piroxicam is a nonsteroidal and non-selective cyclooxygenase (COX) inhibitor which has anti-inflammatory effects. The mechanism of action is mainly by inhibition of the enzyme COX in the arachidonic acid metabolism pathway, resulting in reduced prostaglandin synthesis. In addition, the mechanisms are not completely defined but piroxicam has been reported its antiangiogenic effects and induction of apoptosis in cancer cells, as well as other NSAIDs. (The product is for research purpose only.)
References
- Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy (a review)
- Human synovial mast cell. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs
- Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam
- Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers
- Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
- Piroxicam (a review on physical properties, synthesis, stability, methods of analysis and pharmacokinetics of piroxicam)
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.